We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions.
- Authors
Greenberg, Barry D.; Lemere, Cynthia A.; Barnes, Lisa L.; Hayden, Kathleen M.; Kukull, Walter A.; Oh, Esther S.; Snyder, Peter J.; Supiano, Mark; Dilworth‐Anderson, Peggye
- Abstract
This editorial discusses the need for fully informing patients, particularly minoritized individuals and underrepresented demographic groups, about the potential risks and benefits of anti-amyloid immunotherapies for treating Alzheimer's disease. The editorial highlights the limitations of clinical trials, which have predominantly included a homogeneous White population, and emphasizes the importance of considering health disparities and demographic differences in disease understanding and treatment. It advocates for providing objective and clear information to practitioners and patients, modifying drug labeling to reflect the limitations of the trials, and ensuring an inclusive and safe approach to treating Alzheimer's disease.
- Subjects
ALZHEIMER'S disease; CEREBRAL amyloid angiopathy; DRUG labeling; DEMOGRAPHIC characteristics; IMMUNOTHERAPY; THERAPEUTICS
- Publication
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, Vol 9, Issue 4, p1
- ISSN
2352-8737
- Publication type
Article
- DOI
10.1002/trc2.12426